Innovation in bone healing and tissue repair

Christian Itin - Chairman

Christian Itin serves as Kuros Chairman of the Board (“Chairman”) since the completion of the merger of Kuros Biosurgery with Cytos Biotechnology in January 2016. Dr. Itin is CEO and Chairman of Autolus Inc., London, UK, since March 2016 and November 2014, respectively. From November 2012 to January 2016, he served as Chairman and CEO of Cytos Biotechnology. Before joining Cytos, Dr. Itin was President and CEO of Micromet Inc., which was acquired in 2012 by Amgen, Inc. Over a period of 13 years, he served in a number of senior management roles at Micromet, becoming CEO in 2004. Dr. Itin received a diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he performed post-doctoral research at the Biocenter of Basel University, Switzerland, and at Stanford University School of Medicine, Stanford, California, USA. Dr. Itin also serves as non-executive director of Kymab Ltd, Cambridge, UK. Christian Itin is a Swiss citizen and resident of Germany.

Leanna Caron

Leanna Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health. In this role, Ms. Caron oversees all aspects of commercial development, launch and corporate communications. A seasoned executive, Ms. Caron developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Prior to her current role, Ms. Caron was Vice President and General Manager at Sanofi, overseeing the global commercial operations for Cell Therapy and Regenerative Medicine. She has also held senior positions at Genzyme and Merck in the United States, Canada, and Europe and has led several international teams to successfully launch niche/orphan and block-buster products globally. Ms. Caron has served on the boards of WomenLead and CartiHeal, and currently serves as a strategic advisor to the board of CartiHeal, and is Chairman of the Board and President of Skate Canada. She received her pharmacy degree from the University of Toronto, Canada, and her MBA from Concordia University, Montreal, Canada, and Cornell University, Ithaca/NY, USA. Mrs. Caron is citizen of Canada.

Didier Cowling

Didier Cowling co-founded Kuros in early 2002 and has been its CEO until April 2017. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Arnd Kaltofen

Arnd Kaltofen joined VI Partners in 2001 as a partner focusing on early-stage life science investments. From 1998 to 2001, he built a team dedicated to venture capital transactions in the life science and health care industry for KPMG Corporate Finance. Mr. Kaltofen gained his entrepreneurial experience in several medical device and e-health start-ups where he held various management positions between 1991 and 1998. As an MD, he started his professional career in a university hospital and in medical research (1987 to 1991). Current board memberships include Jenavalve, Inc. and Ventaleon GmbH. In addition to his medical degree, Mr. Kaltofen holds an MBA from Kellogg Graduate Business School, Evanston/IL, USA, and WHU Koblenz, Germany, as well as a Postgraduate Degree in Computer Sciences from TU Munich, Germany. Mr. Kaltofen is Swiss and German citizen.

Jörg Neermann

Jörg Neermann joined LSP as Partner in 2007. Dr. Neermann's prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the Managing Director of Deutsche Bank's DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany, where he invested in the healthcare sector. Dr. Neermann has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Dr. Neermann is currently a Director at Probiodrug, a listed German biotech company active in the area of Alzheimer’s disease. Dr. Neermann holds a Master's degree and a PhD in Biotechnology from the Technical University in Braunschweig, Germany, and MIT in Cambridge/MA, USA. He also studied economics at Harvard Business School, Cambridge/MA, USA. Mr. Neermann is German citizen.

Gerhard Ries

Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharmaceutical industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was co-founder and managing partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs, Leukocare and AOInvest. Dr. Ries holds a MS and a PhD degree in Molecular Biology from the University of Basel, Switzerland, and a MS degree in Biotechnology from the Fachhochschule Weihenstephan, Munich, Germany. Mr. Ries is Swiss and German citizen.

Harry Welten

Harry Welten is Chief Financial Officer (“CFO”) of Kuros. From June 2010 to January 2016 he served as executive vice president and CFO of Cytos. He has more than 20 years of international senior executive experience, sixteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the CFO at Nitec Pharma, which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the CFO at Arpida, which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a director at UBS Warburg in New York/NY, USA, following various senior positions within the UBS Group. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Anokion, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York/NY, USA. Mr. Welten is Swiss citizen.

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Board

Christian Itin
Chairman

Christian Itin serves as Kuros Chairman of the Board (“Chairman”) since the completion of the merger of Kuros Biosurgery with Cytos Biotechnology in January 2016. Dr. Itin is CEO and Chairman of Autolus Inc., London, UK, since March 2016 and November 2014, respectively. From November 2012 to January 2016, he served as Chairman and CEO of Cytos Biotechnology. Before joining Cytos, Dr. Itin was President and CEO of Micromet Inc., which was acquired in 2012 by Amgen, Inc. Over a period of 13 years, he served in a number of senior management roles at Micromet, becoming CEO in 2004. Dr. Itin received a diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he performed post-doctoral research at the Biocenter of Basel University, Switzerland, and at Stanford University School of Medicine, Stanford, California, USA. Dr. Itin also serves as non-executive director of Kymab Ltd, Cambridge, UK. Christian Itin is a Swiss citizen and resident of Germany.

Leanna Caron

Leanna Caron is Executive Vice President and Chief Commercial Officer for AgNovos Healthcare, a company focused on bone health. In this role, Ms. Caron oversees all aspects of commercial development, launch and corporate communications. A seasoned executive, Ms. Caron developed an acumen in business development, strategic planning and partnerships, global marketing, and overall business management. Prior to her current role, Ms. Caron was Vice President and General Manager at Sanofi, overseeing the global commercial operations for Cell Therapy and Regenerative Medicine. She has also held senior positions at Genzyme and Merck in the United States, Canada, and Europe and has led several international teams to successfully launch niche/orphan and block-buster products globally. Ms. Caron has served on the boards of WomenLead and CartiHeal, and currently serves as a strategic advisor to the board of CartiHeal, and is Chairman of the Board and President of Skate Canada. She received her pharmacy degree from the University of Toronto, Canada, and her MBA from Concordia University, Montreal, Canada, and Cornell University, Ithaca/NY, USA. Mrs. Caron is citizen of Canada.

Didier Cowling

Didier Cowling co-founded Kuros in early 2002 and has been its CEO until April 2017. He was also Kuros’ chairman from 2002 to 2007. Prior to co-founding Kuros, Mr. Cowling was co-founder, chairman and CEO of Kuros Therapeutics, a position he held from the founding of that company in 2000 to its successful sale to Straumann in 2002. From 1996 to 2000, Mr. Cowling was Director Business Development for Phairson Medical Ltd., a start-up biomedical company developing wound care products and devices. Previously, he was a Senior Investment Analyst at HSBC, specialising in global pharmaceuticals and healthcare, a post he held for four years. Prior to that, Mr. Cowling was an investment analyst at Nomura Research Institute where he also specialized in the pharmaceutical and healthcare sectors. Mr. Cowling is a graduate of Cambridge University in Natural Sciences, specializing in Organic Chemistry and Biochemistry.

Arnd Kaltofen

Arnd Kaltofen joined VI Partners in 2001 as a partner focusing on early-stage life science investments. From 1998 to 2001, he built a team dedicated to venture capital transactions in the life science and health care industry for KPMG Corporate Finance. Mr. Kaltofen gained his entrepreneurial experience in several medical device and e-health start-ups where he held various management positions between 1991 and 1998. As an MD, he started his professional career in a university hospital and in medical research (1987 to 1991). Current board memberships include Jenavalve, Inc. and Ventaleon GmbH. In addition to his medical degree, Mr. Kaltofen holds an MBA from Kellogg Graduate Business School, Evanston/IL, USA, and WHU Koblenz, Germany, as well as a Postgraduate Degree in Computer Sciences from TU Munich, Germany. Mr. Kaltofen is Swiss and German citizen.

Jörg Neermann

Jörg Neermann joined LSP as Partner in 2007. Dr. Neermann's prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the Managing Director of Deutsche Bank's DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany, where he invested in the healthcare sector. Dr. Neermann has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Dr. Neermann is currently a Director at Probiodrug, a listed German biotech company active in the area of Alzheimer’s disease. Dr. Neermann holds a Master's degree and a PhD in Biotechnology from the Technical University in Braunschweig, Germany, and MIT in Cambridge/MA, USA. He also studied economics at Harvard Business School, Cambridge/MA, USA. Mr. Neermann is German citizen.

Gerhard Ries

Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharmaceutical industry and venture capital experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy and Boehringer Mannheim. Before founding LifeCare Partners, Gerhard was co-founder and managing partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies. Gerhard’s current board memberships include DiaMedCare, Devis Pharma, Leon Nanodrugs, Leukocare and AOInvest. Dr. Ries holds a MS and a PhD degree in Molecular Biology from the University of Basel, Switzerland, and a MS degree in Biotechnology from the Fachhochschule Weihenstephan, Munich, Germany. Mr. Ries is Swiss and German citizen.

Harry Welten

Harry Welten is Chief Financial Officer (“CFO”) of Kuros. From June 2010 to January 2016 he served as executive vice president and CFO of Cytos. He has more than 20 years of international senior executive experience, sixteen of which as chief financial officer in biotech. Prior to joining Cytos, he was the CFO at Nitec Pharma, which was merged with Horizon Pharma and is now listed on Nasdaq. From 2001 to 2009, he was the CFO at Arpida, which he took public in 2005 at the SIX main segment. Prior to joining Arpida, he was a director at UBS Warburg in New York/NY, USA, following various senior positions within the UBS Group. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Anokion, BiognoSYS, ProteoMediX and Horizon Pharma. Furthermore, he is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York/NY, USA. Mr. Welten is Swiss citizen.